Interferon, alpha 17 (IFNA17) Ile184Arg polymorphism and cervical cancer risk

Cancer Letters

Volumn 189, Issue 2, 2003, Pages 183-188

  Kim, Jae Weon ^a   Roh, Ju Won ^b   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a   Lee, Hyo Pyo ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Cervical cancer; Interferon, alpha 17; Polymorphism

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON 17; GENOMIC DNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENE LOCATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IFNA17 GENE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX CANCER;

ALLELES; AMINO ACID SUBSTITUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; INTERFERON-ALPHA; INTERFERONS; KOREA; POINT MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 18744384633     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00548-7     Document Type: Article

References (28)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
2. Central cancer registry center in Korea, Annual report of the central cancer registry in Korea (1998.1∼1998.12), Ministry of Health and Welfare, Seoul, (2000).
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Human Papillomavirus, WHO, Lyon, Vol. 64 (1995).
4. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
5. Hildesheim A. Human papillomavirus variants: implications for natural history studies and vaccine development efforts. J. Natl. Cancer Inst. 89:1997;752-753.
6. Bosch F.X., Munoz N., de Sanjose S., Izarzugaza I., Gili M., Viladiu P., Tormo M.J., Moreo P., Ascunce N., Gonzalez L.C. Risk factors for cervical cancer in Colombia and Spain. Int. J. Cancer. 52:1992;750-758.
7. Haverkos H., Rohrer M., Pickworth W. The cause of invasive cervical cancer could be multifactorial. Biomed. Pharmacother. 54:2000;54-59.
8. Denko N., Schindler C., Koong A., Laderoute K., Green C., Giaccia A. Epigenetic regulation of gene expression in cervical cancer cells by the tumour microenvironment. Clin. Cancer Res. 6:2000;480-487.
9. Wu T.C. Immunology of the human papillomavirus in relation to cancer. Curr. Opin. Immunol. 6:1994;746-754.
10. Frazer I.H. Immunology of papillomavirus infection. Curr. Opin. Immunol. 8:1996;484-491.
11. Murakami M., Gurski K.J., Steller M.A. Human papillomavirus vaccines for cervical cancer. J. Immunol. 22:1999;212-218.
12. Labeit D., Labeit S., Berger M., Gallati H., Rosenberg R., Friese K. Interferon-alpha controls HPV infection in cervix epithelium. Zentralbl. Gynakol. 117:1995;566-577.
13. Maeyer E.D., Maeyer-Guignard D.M. Interferons. Thomson A.W. The Cytokine Handbook. 1994;265-288 Academic Press, Cambridge.
14. Golovleva I., Kandefer-Szerszen M., Beckman L., Lundgren E. Polymorphism in the interferon-alpha gene family. Am. J. Hum. Genet. 59:1996;570-578.
15. Golovleva I., Birgander R., Sjalander A., Lundgren E., Beckman L. Interferon-alpha and p53 alleles involved in nasopharyngeal carcinoma. Carcinogenesis. 18:1997;645-647.
16. Golovleva I., Saha N., Beckman L. Ethnic differences in interferon-alpha allele frequencies. Hum. Hered. 47:1997;185-188.
17. Mizoguchi J., Pitha P.M., Raj N.B. Efficient expression in Escherichia coli of two species of human interferon-alpha and their hybrid molecules. DNA. 4:1985;221-232.
18. Henco K., Brosius J., Fujisawa A., Fujisawa J.I., Haynes J.R., Hochstadt J., Kovacic T., Pasek M., Schambock A., Schmid J. Structural relationship of human interferon alpha genes and pseudogenes. J. Mol. Biol. 185:1985;227-260.
19. Olopade O.I., Bohlander S.K., Pomykala H., Maltepe E., Van Melle E., Le Beau M.M., Diaz M.O. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics. 14:1992;437-443.
20. Schaid D.J., Buetow K., Weeks D.E., Wijsman E., Guo S.W., Ott J. Discovery of cancer susceptibility genes: study designs, analytic approaches, and trends in technology, in: Innovative study designs and analytic approaches to the genetic epidemiology of cancer. J. Natl. Cancer Inst. 26:1999;1-16.
21. Westendorp R.G., Langermans J.A., Huizinga T.W., Elouali A.H., Verweij C.L., Boomsma D.I., Vandenbroucke J.P., Vandenbrouke J.P. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 349:1997;170-173.
22. Knight J.C., Kwiatkowski D. Inherited variability of tumour necrosis factor production and susceptibility to infectious disease. Proc. Assoc. Am. Physicians. 111:1999;290-298.
23. Heresbach D., Alizadeh M., Dabadie A., Le Berre N., Colombel J.F., Yaouanq J., Bretagne J.F., Semana G. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am. J. Gastroenterol. 92:1997;1164-1169.
24. Danis V.A., Millington M., Hyland V.J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin. Exp. Immunol. 99:1995;303-310.
25. Sternik G., Pittis M.G., Gutierrez M., Diez R.A., Sen L. In acute lymphoblastic leukemia deletion of the tumour suppressor gene P16 is associated with abnormal interferon genes. Medicina (B Aires). 58:1998;463-468.
26. Aguiar R.C., Sill H., Goldman J.M., Cross N.C. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. Leukemia. 11:1997;233-238.
27. Wacholder S., Silverman D.T., McLaughlin J.K., Mandel J.S. Selection of controls in case-control studies III; Design options. Am. J. Epidemiol. 135:1992;1042-1050.
28. Kim J.W., Kang S.B., Seo D.K., Choi S.H., Lee C.M., Kim Y.B., Park N.H., Song Y.S., Kang S.B., Lee H.P. Cytologic screening history of 249 patients with cervical cancer. J. Korean Cancer Assoc. 30:1998;1198-1206.